IUC26666-91

Abstract Code: IUC26666-91   Prediction of immune-related adverse events (irAEs) with hematologic markers in patients receiving first-line immune checkpoint inhibitor (ICI)-based therapy in metastatic renal cell carcinoma (mRCC) Winayak 1, X. Li 1, N.J. Salgia 2,...

IUC26658-92

Abstract Code: IUC26658-92   Efficacy Patterns of First-Line Immune Checkpoint Inhibitor Combinations in Metastatic Clear Cell Renal Cell Carcinoma: A Systematic Review and Meta-Analysis Evaluating Ethnic Variations Khanna 1, T. Dey 2, E. Blanchard-Cavagis 3, B....

IUC26657-91

Abstract Code: IUC26657-91   Sex-based Disparities in Metastatic Renal Cell Carcinoma: Real-World Data from Meet-URO33 Study. Zinelli Ronzoni 1, M. Maffezzoli 1, E. Lai 2, E. Verzoni 3, C. Lolli 4, M. Di Napoli 5, A. Signori 6, S. Buti 1, S.E. Rebuzzi 7, D....

IUC26628-89

Abstract Code: IUC26628-89   Real-World Outcomes of Adjuvant Pembrolizumab in Renal Cell Carcinoma: A Single-Centre Experience    Okuma 1, C. Nwankwo 1, M. Cortez 1, M. Chipuriro 1, K. Kumar 1 (1) James Cook University Hospital, Middlesbrough – United...

IUC26562-86

Abstract Code: IUC26562-86   Integrating Transcriptomic Profiles and Clinical Outcomes Across MEET-URO Risk Groups in Metastatic Renal Cell Carcinoma: A Comparative Analysis with the IMDC Framework Neola 1, N. Salgia 2, A. Moradi 2, S.E. Rebuzzi 3, P. Rescigno 4,...

IUC26559-92

Abstract Code: IUC26559-92   Reduced-Dose Pazopanib as First-Line Therapy in Metastatic Renal Cell Carcinoma: Real-World Evidence from an Immunotherapy-Inaccessible Cohort Krishnan M P 1, P. Shenoy 1, N. Devi R 1, A. Menon 1, S. Nawaz 1 (1) Divison of Medical...
error: Content is protected !!